In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Restore Medical Inc.

Division of Medtronic PLC

Latest From Restore Medical Inc.

Alaxo GMBH

Earlier this decade, a German citizen suffering from obstructive sleep apnea (OSA) came up with the idea of mechanically splinting the airways in the throat to ensure free flow of air into the lungs, rather than relying on traditional pressure-based splinting of the airways, as with continuous positive airway pressure therapy (CPAP). That concept became the AlaxoStent from Alaxo GMBH, a self-expandable, shape-memory metal braid that the patient can insert into his nose and throat at night and remove in the morning.

Once Sluggish Sleep Apnea Gets Active

The past year was a busy one in the sleep apnea sector of the respiratory market. All three major segments of the sleep apnea market--sleep testing equipment, continuous positive airway pressure (CPAP) devices, and therapeutic implants--were represented by the year's deals, which include four acquisitions and two venture financings, and we're not even counting the $4.9 billion acquisition of Respironics by Philips, which was announced at the tail end of 2007.

Medtech Venture Capital Heads into Unfamiliar Terrain

The landscape in medtech investing is changing, and one need only look at two signposts to see that this is so: the exit values of VC-backed companies over the past eight years (lower than anticipated), and the amount of time required to achieve those exits (longer than ever before). De Novo Ventures' Richard Ferrari presents the trends that emerge from eight years of venture investing in medical technology companies.
Business Strategies Business Strategies

Medical Device and In Vitro Diagnostics/Research Deal Statistics Quarterly, Q2 2008

Highlights from the Q2 2008 review of device and diagnostics dealmaking: financing for medical device firms was down 9% from the first quarter to $838mm, which consisted mainly of late-stage venture rounds at 43% of the total. Big Pharma was surprisingly active in device acquisitions, with Novartis buying 25% of surgical instruments maker Alcon, and BMS selling off ConvaTec to private equity as part of its "string of pearls" strategy to focus on biotech. Two FOPOs dominated the $300mm financing the IVD/Research industry, while Invitrogen's $6.4bn stock swap for Applera's Applied Biosystems represented 90% of the M&A dollar volume.
Medical Device
See All

Company Information

  • Industry
  • Medical Devices
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
  • Therapeutic Areas
  • Neurology, Nervous System
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Medtronic PLC
  • Senior Management
  • J. Robert Paulson, Pres. & CEO
    Christopher Geyen, SVP & CFO
    Paul J Buscemi, PhD, VP, R&D
    Craig Palmer, SVP, US Sales
  • Contact Info
  • Restore Medical Inc.
    Phone: (651) 634-3111
    2800 Patton Rd.
    St. Paul, MN 55113